Brokerages predict that American Renal Associates Holdings Inc (NYSE:ARA) will announce $189.90 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $188.00 million and the highest estimate coming in at $191.80 million. American Renal Associates reported sales of $177.03 million during the same quarter last year, which indicates a positive year over year growth rate of 7.3%. The firm is expected to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that American Renal Associates will report full-year sales of $189.90 million for the current fiscal year, with estimates ranging from $796.00 million to $808.00 million. For the next year, analysts expect that the business will report sales of $869.50 million per share, with estimates ranging from $864.00 million to $875.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover American Renal Associates.
American Renal Associates (NYSE:ARA) last issued its earnings results on Tuesday, March 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.03. American Renal Associates had a positive return on equity of 14.51% and a negative net margin of 1.00%. The firm had revenue of $194.40 million for the quarter, compared to analysts’ expectations of $195.15 million. During the same period in the previous year, the firm posted $0.26 earnings per share. The business’s revenue was down 2.5% compared to the same quarter last year.
Several equities research analysts have recently issued reports on ARA shares. Leerink Swann reaffirmed an “outperform” rating and issued a $17.00 target price (down from $22.00) on shares of American Renal Associates in a report on Tuesday, November 21st. Zacks Investment Research raised American Renal Associates from a “sell” rating to a “hold” rating in a report on Tuesday, February 20th. Finally, SunTrust Banks set a $20.00 target price on American Renal Associates and gave the stock a “buy” rating in a report on Thursday, December 21st.
Hedge funds have recently modified their holdings of the company. We Are One Seven LLC bought a new stake in American Renal Associates during the fourth quarter worth approximately $131,000. The Manufacturers Life Insurance Company increased its stake in American Renal Associates by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after acquiring an additional 1,443 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in American Renal Associates during the second quarter worth approximately $230,000. Citadel Advisors LLC bought a new stake in American Renal Associates during the third quarter worth approximately $200,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in American Renal Associates during the fourth quarter worth approximately $306,000. 91.64% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ARA stock opened at $22.30 on Wednesday. American Renal Associates has a twelve month low of $9.91 and a twelve month high of $24.07. The company has a debt-to-equity ratio of 4.28, a current ratio of 1.20 and a quick ratio of 1.17. The stock has a market capitalization of $729.57, a PE ratio of -85.77, a PEG ratio of 1.56 and a beta of 2.08.
WARNING: “Analysts Expect American Renal Associates Holdings Inc (ARA) Will Announce Quarterly Sales of $189.90 Million” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/21/analysts-expect-american-renal-associates-holdings-inc-ara-will-announce-quarterly-sales-of-189-90-million.html.
About American Renal Associates
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Get a free copy of the Zacks research report on American Renal Associates (ARA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.